APA

Frasci G., Comella P., Carreca I., DeCataldis G., Muci D., Brunetti C., Russo A., Palmeri S., D'Aniello R., Giordano R., D'Aiuto M. & Comella G. (20050818). Weekly dose-dense cisplatin-epirubicin-paclitaxel administration with granulocyte colony-stimulating factor support does not substantially improve prognosis in extensive disease small-cell lung cancer. A SICOG phase II study. : Oncology.

Chicago

Frasci Giuseppe, Comella Pasquale, Carreca Ignazio, DeCataldis Giuseppe, Muci Domenico, Brunetti Cosimo, Russo Anna, Palmeri Sergio, D'Aniello Roberta, Giordano Renato, D'Aiuto Massimiliano and Comella Giuseppe. 20050818. Weekly dose-dense cisplatin-epirubicin-paclitaxel administration with granulocyte colony-stimulating factor support does not substantially improve prognosis in extensive disease small-cell lung cancer. A SICOG phase II study. : Oncology.

Harvard

Frasci G., Comella P., Carreca I., DeCataldis G., Muci D., Brunetti C., Russo A., Palmeri S., D'Aniello R., Giordano R., D'Aiuto M. and Comella G. (20050818). Weekly dose-dense cisplatin-epirubicin-paclitaxel administration with granulocyte colony-stimulating factor support does not substantially improve prognosis in extensive disease small-cell lung cancer. A SICOG phase II study. : Oncology.

MLA

Frasci Giuseppe, Comella Pasquale, Carreca Ignazio, DeCataldis Giuseppe, Muci Domenico, Brunetti Cosimo, Russo Anna, Palmeri Sergio, D'Aniello Roberta, Giordano Renato, D'Aiuto Massimiliano and Comella Giuseppe. Weekly dose-dense cisplatin-epirubicin-paclitaxel administration with granulocyte colony-stimulating factor support does not substantially improve prognosis in extensive disease small-cell lung cancer. A SICOG phase II study. : Oncology. 20050818.